Mexidol FORTE 250 mg, 40 pcs.

Meksidol ^®  FORTE 250 is an inhibitor of free radical processes, membrane protectors having antihypoxic, stress-protective, neuroprotective, antiepileptic and anxiolytic action. Belongs to the class of 3-hydroxypyridines.

The mechanism of drug action Meksidol ^®  FORTE 250 due antioxidant, antihypoxic and membrane action. The drug inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, improves the structure and function of the cell membrane. Meksidol ^®  FORTE 250 modulates the activity of membrane bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine), which increases their binding ability with ligands contributes to maintaining structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. Mexidol ^® FORTE 250 increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria.

Increases the body's resistance to the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotic drugs).

In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes - phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports the activation of aerobic glycolysis that develops during acute ischemia and promotes the restoration of mitochondrial redox processes under conditions of hypoxia, increases the synthesis of ATP and creatine phosphate. Provides the integrity of the morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, increases the effectiveness of therapy, reduces the incidence of arrhythmias and intracardiac conduction disorders. Normalizes metabolic processes in the ischemic myocardium, increases the antianginal activity of nitrates,

Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

Improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and LDL.

The antistress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wakefulness cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.

Meksidol ^®  FORTE 250 has a pronounced effect when antitoxic withdrawal syndrome. Eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disturbances, autonomic functions, and is also able to relieve cognitive impairment caused by prolonged intake of ethanol and its cancellation. Under the influence of the drug, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects.

Meksidol ^®  FORTE 250 improves the functional state of ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, contributes to the preservation of the integrity of cardiomyocytes and the maintenance of their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

• consequences of acute disorders of cerebral circulation, incl. after transient ischemic attacks, in the phase of subcompensation (as a preventive course);
• minor traumatic brain injury, the consequences of traumatic brain injury;
• encephalopathy of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed);
• vegetative dystonia syndrome;
• mild cognitive disorders of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like states;
• IHD (as part of complex therapy);
• relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;
• conditions after acute intoxication with antipsychotic drugs;
• asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
• exposure to extreme (stress) factors.

• acute disorders of liver and kidney function;
• increased individual sensitivity to the drug.

Due to insufficient knowledge of the effect of the drug - children's age, pregnancy, breastfeeding.

The appearance of individual side reactions of a dyspeptic nature, allergic reactions is possible.

Meksidol ^®  FORTE 250 combined with all drugs used to treat systemic diseases.

Strengthens the effect of benzodiazepine drugs, antidepressants, anxiolytics, antiparkinsonian (levodopa) and antiepileptic drugs (carbamazepine), nitrates.

Reduces the toxic effect of ethanol.

Inside, 250 mg 3 times / day.

The initial dose is 250 mg (1 tab.) 1-2 times / day with a gradual increase until a therapeutic effect is obtained; the maximum daily dose is 750 mg (3 tab.).

Duration of treatment is 2-6 weeks; for relief of alcohol withdrawal - 5-7 days. The duration of the course of therapy in patients with coronary artery disease is at least 1.5-2 months.

Repeated courses (on the recommendation of a doctor), preferably carried out in the spring and autumn periods.

Symptoms: drowsiness, insomnia.

Treatment: due to low toxicity, overdose is unlikely. Treatment, as a rule, is not required, the symptoms disappear on their own within 24 hours. With pronounced manifestations, supportive and symptomatic treatment is carried out.

Absorption and distribution

It is rapidly absorbed when taken orally. C _max  at doses of 400-500 mg is 3.5-4.0 μg / ml.

It is quickly distributed in organs and tissues. The average retention time of the drug in the body when taken orally is 4.9-5.2 hours.

Metabolism

It is metabolized in the liver by glucuron conjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, is formed in large quantities and is found in urine for 1-2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates.

Withdrawal

T _1/2  when taken orally - 2-2.6 hours. It is quickly excreted in the urine, mainly in the form of metabolites and in small amounts - unchanged. It is most intensively excreted during the first 4 hours after taking the drug. The indicators of excretion in the urine of unchanged drug and metabolites have individual variability.

Influence on the ability to drive vehicles and use mechanisms

During the period of taking the drug, care should be taken when working that requires the speed of psychophysical reactions (driving vehicles, mechanisms, etc.).